Shock - Classification and Pathophysiological Principles of Therapeutics

Current Cardiology Reviews
Olga N KislitsinaClyde W Yancy

Abstract

The management of patients with shock is extremely challenging because of the myriad of possible clinical presentations in cardiogenic shock, septic shock and hypovolemic shock and the limitations of contemporary therapeutic options. The treatment of shock includes the administration of endogenous catecholamines (epinephrine, norepinephrine, and dopamine) as well as various vasopressor agents that have shown efficacy in the treatment of the various types of shock. In addition to the endogenous catecholamines, dobutamine, isoproterenol, phenylephrine, and milrinone have served as the mainstays of shock therapy for several decades. Recently, experimental studies have suggested that newer agents such as vasopressin, selepressin, calcium-sensitizing agents like levosimendan, cardiac-specific myosin activators like omecamtiv mecarbil (OM), istaroxime, and natriuretic peptides like nesiritide can enhance shock therapy, especially when shock presents a more complex clinical picture than normal. However, their ability to improve clinical outcomes remains to be proven. It is the purpose of this review to describe the mechanism of action, dosage requirements, advantages and disadvantages, and specific indications and contraindications fo...Continue Reading

References

Oct 11, 1992·Journal of Cardiothoracic and Vascular Anesthesia·J F ButterworthG P Zaloga
Oct 1, 1987·The American Journal of the Medical Sciences·R R Ruffolo
Oct 1, 1973·Medical History·G T Anderson, D K Anderson
May 1, 1998·American Journal of Respiratory and Critical Care Medicine·J LevrautD Grimaud
Feb 24, 2001·Cardiology in Review·M ArgenzianoE A Rose
Dec 19, 2001·Journal of Cellular Physiology·K SinghW S Colucci
Mar 23, 2002·Experimental Biology and Medicine·Johnathan D TuneEric O Feigl
Apr 6, 2005·Annals of Internal Medicine·Jan O FriedrichJoseph Beyene
Jun 25, 2005·Current Medicinal Chemistry. Cardiovascular and Hematological Agents·Ioannis A ParaskevaidisDimitios Th Kremastinos
Jul 28, 2005·JAMA : the Journal of the American Medical Association·Anvar BabaevUNKNOWN NRMI Investigators
Oct 11, 2005·Critical Care Medicine·Bruno LevyUNKNOWN College Interregional des Réanimateurs du Nord-Est
May 24, 2006·Expert Review of Cardiovascular Therapy·Douglas G Tilley, Howard A Rockman
Oct 20, 2006·The New England Journal of Medicine·James A Russell
Mar 17, 2007·Annals of Medicine·Lasse Lehtonen, Pentti Põder
Mar 23, 2007·Anesthesia and Analgesia·Stefan G De HertPhilippe J Van der Linden
May 3, 2007·JAMA : the Journal of the American Medical Association·Alexandre MebazaaUNKNOWN SURVIVE Investigators
Oct 19, 2007·Critical Care Medicine·Günter LucknerMartin W Dünser
Jul 26, 2008·Intensive Care Medicine·John A MyburghUNKNOWN CAT Study investigators
Sep 4, 2008·Circulation·Christopher B Overgaard, Vladimír Dzavík
Nov 20, 2008·Critical Care : the Official Journal of the Critical Care Forum·Andrea MorelliMartin Westphal
Aug 12, 2009·Critical Care : the Official Journal of the Critical Care Forum·Andrea MorelliMartin Westphal
Sep 10, 2009·JAMA : the Journal of the American Medical Association·Nora D VolkowJames M Swanson

❮ Previous
Next ❯

Citations

Oct 7, 2019·Prostaglandins & Other Lipid Mediators·Bahar TunctanKafait U Malik
Feb 23, 2021·Journal of Diabetes and Its Complications·Johannes WikstromYixin Wang
Jun 5, 2021·South African Family Practice : Official Journal of the South African Academy of Family Practice/Primary Care·David G Bishop, Simon P D P Le Roux
Jun 17, 2021·Experimental Biology and Medicine·Peña-Mercado EduardoBeltran Nohra E
Jul 30, 2021·Journal of Cardiac Surgery·Richard Thalappillil, Christopher W Tam

❮ Previous
Next ❯

Software Mentioned

HF

Related Concepts

Related Feeds

Cardiogenic Shock

Cardiogenic shock is a devastating consequence of acute myocardial infarction and is associated with an extremely high mortality. Here is the latest research.